Business
Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results
- 3Q21 net sales of $131.6 million, a 9% increase over 3Q20 - FDA meeting scheduled to discuss next steps towards a resubmission of the pimavanserin sNDA SAN
About this update from Acadia Pharmaceuticals Inc.
[{"type":"text","content":"\n- 3Q21 net sales of $131.6 million, a 9% increase over 3Q20\n\n- FDA meeting scheduled to discuss next steps towards a resubmission of the pimavanserin sNDA\n\n SAN DIEGO--(BUSINESS WIRE)--\nAcadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2021.\n\n“Our third-quarter results reflect volume growth across all channels and our strong relative performance underscores our commercial team’s ability to drive sales of NUPLAZID in a challenging environment,” said Steve Davis, Chief Executive Officer. “As we close out the year, we will meet with the FDA to discuss additional analyses supporting a potential resubmission of our sNDA for pimavanserin focused on specific subgroups of dementia. In addition, we look forward to announcing results from our ongoing Phase 3 LAVENDER study of trofinetide for the treatment of Rett syndrome.”\n\nCompany Updates\n\n\nScheduled meeting with the FDA to discuss additional analyses supporting a potential resubmission of the pimavanserin sNDA focused on specific subgroups of dementia. Acadia plans to provide an update following this meeting around year-end.\n\n\n\nTop-line results from the Phase 3 LAVENDER study evaluating trofinetide for the treatment of Rett syndrome are expected in the fourth quarter of 2021.\n\n\n\nTop-line results from the Phase 2 study of ACP-044 for the treatment of postoperative pain following bunionectomy surgery are expected in the first quarter of 2022.\n\n\n\nThree data presentations featuring new analyses of Medicare claims data on dementia-related psychosis outcomes were presented at the Psych Congress 2021 demonstrating the high unmet need in dementia-related psychosis and providing further evidence of the sub-optimal outcomes associated with the use of dopaminergic atypical antipsychotic treatments in managing dementia-related hallucinations and delusions, along with the related cost burdens.\n\n\n\nA scientific presentation on pimavanserin for the treatment of hallucinations and delusions in patients with Parkinson’s disease dementia will be shared at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference.\n\n\n\nBrendan Teehan has been promoted to Executive Vice President, Chief Operating Officer, Head of Commercial.\n\n\n\nJulie Fisher has been promoted to Senior Vice President, Market...